A Phase II/III Trial of Human Anti-CMV Monoclonal Antibody MSL 109 (MACRT) - Full Text View

Sponsored by:	National Institute of Allergy and Infectious Diseases (NIAID)
Information provided by:	National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier:	NCT00000836

Purpose

To compare the safety and efficacy of sevirumab (MSL 109; Protovir), human anti-cytomegalovirus (CMV) monoclonal antibody, plus active primary treatment versus placebo plus active primary treatment in AIDS patients with newly diagnosed and relapsed CMV retinitis.

Ganciclovir and foscarnet are used for treatment of CMV retinitis, but cause hematologic toxicity and nephrotoxicity, respectively. Despite continued maintenance therapy with these drugs, relapse occurs in 85 percent of patients within 4 months. Studies suggest that MSL 109, a human monoclonal antibody, when given with either ganciclovir or foscarnet, may increase initial response and prolong time to progression in patients with CMV retinitis.

Condition	Intervention	Phase
Cytomegalovirus Retinitis HIV Infections	Drug: Sevirumab	Phase II

MedlinePlus related topics: AIDS Cytomegalovirus Infections

Drug Information available for: Immunoglobulins Globulin, Immune Sevirumab

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment
Official Title:	A Phase II/III Trial of Human Anti-CMV Monoclonal Antibody MSL 109 (MACRT)

Further study details as provided by National Institute of Allergy and Infectious Diseases (NIAID):

Estimated Enrollment:

300

Detailed Description:

Ganciclovir and foscarnet are used for treatment of CMV retinitis, but cause hematologic toxicity and nephrotoxicity, respectively. Despite continued maintenance therapy with these drugs, relapse occurs in 85 percent of patients within 4 months. Studies suggest that MSL 109, a human monoclonal antibody, when given with either ganciclovir or foscarnet, may increase initial response and prolong time to progression in patients with CMV retinitis.

Patients are randomized to receive either MSL 109 or placebo every 2 weeks as supplemental therapy to primary CMV treatment.

Eligibility

Ages Eligible for Study:	13 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria

Concurrent Medication: Required:

Primary CMV treatment.

Patients must have:

AIDS.
Active CMV retinitis.
At least one photographable lesion of one-quarter or more optic disc area in size.
Undergoing primary treatment for CMV retinitis that is not contraindicated with MSL 109.
Visual acuity in at least one eye of 3 or more letters on Early Treatment Diabetic Retinopathy Study ( ETDRS ) chart at 1 meter distance ( Snellen equivalent 5/200 ). Note:
Exceptions may be made if visual acuity impairment is possibly reversible and there is at least light perception in that eye.

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms or conditions are excluded:

Retinal detachment not scheduled for surgical repair.
Media opacity that precludes visualization of the fundus.
Active medical problems sufficient to hinder study compliance.

Concurrent Medication:

Excluded:

IVIG.
CMV immune globulin ( CMVIG ).
Interferon alpha.
Interferon gamma.
Interleukin-2 ( IL-2 ).

Drug or alcohol abuse sufficient to hinder study compliance.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000836

Locations

United States, California
UCSF - San Francisco Gen Hosp
San Francisco, California, United States, 94143
UCSD - Shiley Eye Ctr / SOCA
La Jolla, California, United States, 920930946
UCLA - Jules Stein Eye Institute / SOCA
Los Angeles, California, United States, 900957003
United States, Illinois
Northwestern Univ / SOCA
Chicago, Illinois, United States, 60611
United States, Maryland
Johns Hopkins Hosp / SOCA
Baltimore, Maryland, United States, 212879217
United States, New York
New York Univ Med Ctr / SOCA
New York, New York, United States, 10016

Sponsors and Collaborators

National Institute of Allergy and Infectious Diseases (NIAID)

More Information

Study ID Numbers:	ACTG 294
Study First Received:	November 2, 1999
Last Updated:	June 23, 2005
ClinicalTrials.gov Identifier:	NCT00000836
Health Authority:	United States: Federal Government

Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID):

AIDS-Related Opportunistic Infections
Acquired Immunodeficiency Syndrome
Antibodies, Monoclonal
Cytomegalovirus Retinitis

Study placed in the following topic categories:

Opportunistic Infections
Sexually Transmitted Diseases, Viral
Eye Diseases
Eye Infections
Acquired Immunodeficiency Syndrome
Cytomegalovirus Retinitis
Retinitis
Cytomegalovirus
Immunologic Deficiency Syndromes
Herpesviridae Infections
Antibodies, Monoclonal
Cytomegalovirus retinitis

Virus Diseases
Antibodies
HIV Infections
AIDS-Related Opportunistic Infections
Sexually Transmitted Diseases
Cytomegalovirus Infections
DNA Virus Infections
Cytomegalic inclusion disease
Retroviridae Infections
Retinal Diseases
Immunoglobulins

Additional relevant MeSH terms:

RNA Virus Infections
Slow Virus Diseases
Immunologic Factors
Eye Infections, Viral
Immune System Diseases

Physiological Effects of Drugs
Lentivirus Infections
Infection
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 15, 2009